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Preparation and in vitro characterization of 
non-effervescent floating drug delivery system of poorly  
soluble drug, carvedilol phosphate
The objective of the study was to enhance the solubility of 
carvedilol phosphate and to formulate it into non-efferves-
cent floating tablets using swellable polymers. Solid disper-
sions (SD) of carvedilol were prepared with hydrophilic 
carriers such as polyvinylpyrrolidone and poloxamer to 
enhance solubility. Non-effervescent floating tablets were 
prepared with a combination of optimized solid disper-
sions and release retarding polymers/swellable polymers 
such as xanthan gum and polyethylene oxide. Tablets were 
evaluated for physicochemical properties such as hardness, 
thickness and buoyancy. SD prepared with the drug to po-
loxamer ratio of 1:4 by melt granulation showed a higher 
dissolution rate than all other dispersions. Formulations 
containing 40 mg of polyethylene oxide (C-P40) and 50 mg 
xanthan gum (C-X50) were found to be best, with the drug 
retardation up to 12 hours. Optimized formulations were 
characterized using FTIR and DSC and no drug and ex-
cipient interactions were detected.
Keywords: carvedilol phosphate, solid dispersion, 
non-effervescent, floating tablets
Carvedilol phosphate is a non-selective beta-blocker, prescribed for the treatment of 
angina, hypertension and congestive heart failure. The reported systemic bioavailability 
of carvedilol phosphate is 24 % after oral administration (1). The drug reaches peak plasma 
concentration in 1–2 h with an elimination half-life of 7 to 10 h (1, 2). This drug has a narrow 
absorption window in the upper gastrointestinal tract and it would benefit from a gastro-
retentive delivery system.
Floating drug delivery system (FDDS) is a gastroretentive system that can be efferves-
cent or non-effervescent. Wu et al. (3) prepared floating sustained release tablets of ni-
modipine using HPMC and PEG 6000. Prior to formulation of floating tablets, nimodipine 
was incorporated into a poloxamer-188 solid dispersion, whereafter it was directly com-
pressed into floating tablets. It was observed that by increasing the HPMC and decreasing 
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the PEG 6000 content, a decline in in vitro release of nimodipine occurred. Shilpa et al. (4) 
formulated a bilayer floating tablet of carvedilol phosphate using Ocimum basilicum muci-
lage and hypromellose. The release rate and floating characteristics were effectively altered 
by varying the polymer to gas-generating agent ratio. Swelling polymers and the gas-gene-
rating agent produced stable persistent floatation. The results showed that floating tablets 
are a feasible approach for sustained release preparation of carvedilol phosphate. Xanthan 
gum and polyethylene oxide (PEO) were found to have the potential in development of 
FDDS of various drugs with floating time of 12 hours and 98 % drug release (5–7). Even 
though, research findings on the floating drug delivery of carvedilol phosphate are avail-
able, majority of them are effervescent systems only. In the present research, the authors try 
to explore the non-effervescent floating drug delivery system of carvedilol phosphate with-
out using any gas generating agent. Swellable polymers such as PEO and xanthan gum and 
matrix ballooning inducers such as crospovidone were used in the formulation, which may 
lead to floating of the carvedilol phosphate dosage form in gastric medium.
Poor solubility of carvedilol phosphate in acidic pH was enhanced by preparing solid 
dispersions (SDs) with poloxamer and polyvinylpyrrolidone (PVP) (8, 9). In the present 
study, comparisons between the two carriers in different solid dispersions (obtained by 
solvent evaporation and melt granulation) were investigated.
EXPERIMENTAL
Materials
Carvedilol phosphate was purchased from Sree Sai Chemicals, India. Poloxamer 188, 
xanthan gum, polyvinylpyrrolidone (PVP K30), polyethylene oxide WSR 303 (Polyox® 
WSR 303), lactose and magnesium stearate was purchased from Labchem Sdn Bhd. Malay-
sia. Other materials used were of analytical grade.
Preparation of solid dispersions
The SD formulations were prepared by the solvent evaporation and melt granulation 
methods with different drug-to-carrier ratios. Solvent evaporation using drug/carrier (PVP/ 
poloxamer) ratios 1:1, 1:2 and 1:3 and melt granulation using drug/poloxamer ratios 1:1, 
1:2, 1:3, 1:4, 1:5 and 1:6.
Solvent evaporation. – Solid dispersions of carvedilol phosphate were prepared with 
PVP poloxamer in drug-to-carrier ratios of 1:1, 1:2 and 1:3 by the conventional solvent 
evaporation technique. Carrier solution was prepared by dissolving required quantities in 
15 mL of methanol in a beaker under continuous stirring (for 1:1, 1:2 and 1:3 ratios 1, 2 and 
3 g of carrier, respectively). An appropriate mass of carvedilol phosphate (1 g) was dis-
solved in 15 mL of methanol so as to obtain 0.06 % m/V of drug solution. Both solutions 
were mixed and stirred until formation of a clear solution. If any precipitation was ob-
served, a volume was adjusted with methanol to make a clear saturated solution. Solution 
was evaporated at 40–50 °C to obtain a solid mixture and further dried in a desiccator for 
24 h to remove residual solvents. Dried mass was collected, sifted through a 60 mesh (250 
µm) sieve and packed in a closed container.
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Melt granulation. – Accurately weighed poloxamer 188 (for 1:1, 1:2, 1:3, 1:4, 1:5 and 1:6 
ratios containing 1, 2, 3, 4, 5 and 6 g of poloxamer respectively) was melted at 50–58 oC 
using a hot plate. The required quantity of drug (1 g at each ratio) was added to the molten 
mass under continuous stirring until it dispersed completely. The dispersion was then so-
lidified by cooling in an ice bath for 10–15 min. Resultant product was placed in a desicca-
tor for 24 h, collected, sifted through a 60 mesh (250 µm) sieve and packed in a closed 
container.
Due to the high melting point of PVP (150 oC), melt granulation was not feasible with 
PVP.
Physical mixtures were prepared by simple geometric mixing of two pure solid com-
ponents with a spatula, followed by sieving through a sieve 60 (250 µm).
Characterization of SDs
Content uniformity. – Accurately weighed SDs were dissolved in 15 mL of methanol and 
made up to 100 mL with 0.1 mol L–1 HCl. The solution was further diluted with 0.1 mol L–1 
HCl until it reached a drug concentration of 10 mol L–1 and measured for drug content 
spectrophotometrically at 241 nm (Perkin Elmer double beam UV-Vis spectrophotometer, 
Perkin Elmer, USA)
In vitro dissolution studies. – The release of carvedilol phosphate from SDs was investi-
gated using a dissolution tester (paddle type) (Electrolab, India) according to USP 2011, 
Revision bulletin (10). SDs equivalent to 10 mg of the drug were added to the dissolution 
medium (900 mL of 0.1 mol L–1 HCl), maintained at 37 ± 0.5 oC at a speed of 50 rpm. A 5-mL 
aliquot was withdrawn at regular intervals (5, 10, 20, 30, 45 and 60 min) and replaced with 
the same volume of fresh dissolution medium. The obtained samples were filtered and 
measured spectrophotometrically at 241 nm.
Preparation of non-effervescent floating tablets
Direct compression method was followed for the preparation of non-effervescent 
floating tablets of carvedilol phosphate. Required quantities of solid dispersion and other 
excipients as mentioned in Table I were weighed accurately, and sifted through a 40 mesh 
(420 µm) separately. Solid dispersion was geometrically mixed with PEO/xanthan gum 
until a homogeneous blend was achieved. Crospovidone was then added to the above 
blend, followed by magnesium stearate (1 %, m/m). The flow property of the final blend 
was found to be satisfactory to allow the mixture to be directly compressed into tablets on 
a 10-station rotary tablet punching machine (M/s. Cadmach Machinery, Co. Pvt. Ltd., In-
dia) using 8-mm round plain punches and hardness of 3–4 kg cm–2.
Characterization of floating tablets
Five tablets were randomly selected and measured for hardness using a Monsanto 
hardness tester (Campbell Electronics, India). Five tablets were randomly selected and 
measured for thickness with a vernier caliper (Mitutoyo, Japan) (11).
In vitro buoyancy studies. – Tablets were placed in a dissolution vessel containing 900 
mL of 0.1 mol L–1 HCl. The time taken for the tablet to rise to the surface of the dissolution 
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medium (floating lag time) and total duration for the tablet to remain on the surface (total 
floating time) were recorded (11).
In vitro dissolution studies. – In vitro release of carvedilol phosphate from the floating 
tablets was studied using a dissolution tester (paddle type) (Electrolab, India) in 900 mL of 
0.1 mol L–1 HCl, maintained at 37 ± 0.5 oC at a speed of 50 rpm for 12 hours. The release of 
carvedilol phosphate was measured by withdrawing 5-mL aliquots at regular intervals 
(0.5, 1, 2, 4, 6, 8, 10, 12 h) and replacing the same volume with fresh dissolution medium. 
The withdrawn samples were filtered and analyzed spectrophotometrically at 241 nm.
Fourier transform infrared spectroscopy (FTIR)
FTIR studies were performed on the drug, poloxamer, SD, xanthan gum, PEO and 
optimized tablets. Samples were analyzed by the potassium bromide pellet method; pellets 
had been prepared by gently mixing 1 mg of the sample with 200 mg of potassium bro-
mide. The spectra were scanned using an IR spectrophotometer (Shimadzu, FTIR 8700, Ja-
pan) in the region between 4000 and 400 cm–1.
Differential scanning calorimetry (DSC)
DSC analyses of the drug, poloxamer, SD, xanthan gum, PEO and optimized tablets 
were carried out on a Mettler Toledo DSC (Mettler-Toledo AG, Switzerland). Samples (3–10 
mg) were heated under a nitrogen atmosphere in an aluminium crucible at a heating rate 
of 10 oC min–1 over the temperature range of 0 to 200 oC.
Table I. Composition of non-effervescent floating tablets of carvedilol phosphate
Ingredient (mg)
Formulation code
C-P30 C-P40 C-P50 C-X25 C-X40 C-X50
Carvedilol phosphate solid dispersiona 54.5 54.5 54.5 54.5 54.5 54.5
Polyethylene oxide 30.0 40.0 50.0 – – –
Xanthan gum – – – 25.0 40.0 50.0
Crospovidone 64.0 54.0 44.0 50.0 54.0 44.0
Lactose – – – 19.0 – –
Magnesium stearate 1.5 1.5 1.5 1.5 1.5 1.5
Total mass (mg) 150 150 150 150 150 150
a 54.5 mg of drug was taken based on the content uniformity test of the SDs
C-P (carvedilol phosphate-PEO-crospovidone) 
C-X (carvedilol phosphate-xanthan gum-crospovidone) 
PEO – polyethylene oxide WSR 303
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RESULTS AND DISCUSSION
In vitro dissolution of solid dispersions
The results of in vitro dissolution tests are shown in Table II. Dissolution of pure drug 
was low with only 47.7 % of drug release within 1 hour. There were no significant changes 
in the dissolution profile of carvedilol phosphate physical mixtures compared to pure 
drug. All the SDs revealed improved dissolution of carvedilol phosphate compared to the 
pure drug. On increasing the quantity of poloxamer/PVP, the SDs revealed an increased 
dissolution rate of carvedilol phosphate for both techniques (solvent evaporation and melt 
granulation). The highest dissolution rate was observed at the drug-to-carrier ratio of 1:3. 
The order of increase in the dissolved drug profile from SDS was C-PVP SE < C-POL SE < 
C-POL MG.
Table II. Percentage of drug released from the prepared SDs, physical mixtures and pure drug
Formulation
Cumulative drug released (%) after (min)a
5 10 20 30 45 60 
Carvedilol phosphate 14.4 ± 0.6 23.5 ± 1.00 29.4 ± 1.45 35.2 ± 1.41 43.0 ± 1.24 47.7 ± 0.99
Physical Mixture (C-PVP 1:3) 16.7 ± 0.9 26.2 ± 0.61 32.4 ± 0.76 39.8 ± 0.45 47.5 ± 0.23 54.1 ± 0.12
Physical Mixture (C-POL 1:4) 22.8 ± 0.1 34.1 ± 0.34 48.4 ± 0.18 55.9 ± 0.52 60.1 ± 0.29 62.7 ± 0.26
C-PVP SE (1:1) 56.0 ± 1.0 58.4 ± 1.56 62.0 ± 0.28 64.1 ± 2.19 66.2 ± 1.70 67.0 ± 1.59
C-PVP SE (1:2) 67.0 ± 1.8 68.5 ± 0.14 69.6 ± 0.69 70.0 ± 1.27 71.4 ± 1.55 72.6 ± 1.05
C-PVP SE (1:3) 70.9 ± 0.6 78.3 ± 0.85 78.5 ± 1.13 79.0 ± 0.71 79.2 ± 0.61 79.4 ± 0.49
C-POL SE (1:1) 46.4 ± 1.7 65.8 ± 2.12 73.5 ± 1.91 74.4 ± 1.27 75.2 ± 0.99 75.7 ± 1.26
C-POL SE (1:2) 72.0 ± 0.3 78.0 ± 0.57 78.6 ± 0.71 79.1 ± 0.91 79.8 ± 0.28 80.2 ± 0.15
C-POL SE (1:3) 72.6 ± 1.4 82.5 ± 1.57 83.4 ± 1.27 83.9 ± 1.24 84.3 ± 0.42 84.5 ± 0.28
C-POL MG (1:1) 54.0 ± 0.6 71.3 ± 1.13 74.0 ± 0.80 75.3 ± 0.57 76.2 ± 0.21 78.9 ± 1.07
C-POL MG (1:2) 78.4 ± 0.5 80.2 ± 1.70 81.3 ± 0.42 81.9 ± 0.48 82.4 ± 0.64 83.1 ± 0.39
C-POL MG (1:3) 85.2 ± 0.7 89.4 ± 2.26 89.7 ± 2.10 90.0 ± 2.55 90.7 ± 1.84 90.9 ± 1.87
C-POL MG (1:4) 90.1 ± 0.1 92.8 ± 0.53 93.3 ± 1.12 93.5 ± 1.30 94.4 ± 1.26 95.6 ± 1.70
C-POL MG (1:5) 79.8 ± 1.2 87.9 ± 1.47 88.1 ± 1.19 88.6 ± 1.02 90.6 ± 0.92 95.6 ± 1.13
C-POL MG (1:6) 70.5 ± 1.8 87.0 ± 1.32 87.3 ± 1.20 87.9 ± 1.24 90.1 ± 1.61 94.6 ± 1.41
a Mean ± SD, n = 3.
SE – solvent evaporation 
MG – melt granulation 
PVP – polyvinyl pyrrolidone (PVP K30) 
POL – poloxamer 188
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Possible explanations for the increased dissolution rates from SDs include the solubi-
lization effect of the carrier, improved drug wettability and reduced drug particle size (12). 
Based on the results, the melt granulation method was found to be suitable for solid disper-
sion preparation using poloxamer. However, the percentage of drug release at the end of 1 
hour was found to be only 90.9 % with the C-POL MG (1:3) formulation. Therefore, higher 
drug-to-poloxamer ratios (1:4, 1:5, 1:6) were used in melt granulation. Comparison of the 
dissolution profiles is given in Table II. C-POL MG (1:4), C-POL MG (1:5) and C-POL MG 
(1:6) showed maximal cumulative drug release of 95.6, 95.4 and 94.6 %, respectively, with 
similar drug release patterns suggesting that the increasing of the drug-to-poloxamer ratio 
above 1:4 did not increase the release rate of the drug. This might be due to formation of a 
carrier layer around the drug particles, which may not allow the drug to come out of the 
dispersion (13). Formulation C-POL MG (1:4) was selected as the optimized batch to pre-
pare tablets.
Characterization of floating tablets
Physical characteristics of the prepared tablets are shown in Table III. All the formula-
tions were found to be of good quality.
The in vitro buoyancies of the tablets are shown in Table III. The floating lag time of the 
xanthan gum and PEO formulations was lower than 10 and 30 s, respectively. The polymer 
(either xanthan gum or PEO) and crospovidone swell in contact with gastric fluids and at-
tain a bulk density of less than 1; therefore they floated on the gastric fluid (14). The swollen 
matrix imparts buoyancy to the dosage form. It was observed that all tablet formulations 
floated longer than 12 h, excluding formulations C-X25 and C-X40 which disintegrated in 
2 and 6 hours, respectively. These might be due to the high amount of crospovidone in the 
formulations and rapid hydration of xanthan gum (15).
Table III. Physical parameters of carvedilol phosphate floating tablets
Formulation code Hardness (kg/cm2) Thickness (mm) Floating lag time (s) Total floating time (h)
C-P30 3–4 2.98 ± 0.19 30 ± 1.3 > 12
C-P40 3–4 2.97 ± 0.08 31 ± 1.0 > 12
C-P50 3–4 2.98 ± 0.01 30 ± 1.1 > 12
C-X25 3–4 2.97 ± 0.18 10 ± 0.5  < 2
C-X40 3–4 3.00 ± 0.20   9 ± 0.8  < 6
C-X50 3–4 3.10 ± 0.34   9 ± 0.9 > 12
Mean ± SD; n = 3.
In vitro drug release
The in vitro drug release data is shown in Fig. 1 for all six tablet formulations. Release 
profiles of different formulations show that C-P30 showed complete drug release within 10 
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hours. Formulations C-P40, C-X25, C-X40 and C-X50 released maximum drug at the end of 
11, 1, 4 and 12 hours, respectively. The drug release was retarded with the increase in poly-
mer concentration. Formulation C-P50 showed the lowest drug release (59.7 ± 0.4 %) after 
12 hours. This may be due to higher polymer concentration to induce formation of larger 
viscous gel layer, thus increasing the diffusional path length of the drug (16). Formulation 
C-X25 shows burst release of 80.7 % of the drug in 30 min, which may be because erosion 
occurred before complete swelling could take place. Drug release from the matrix is de-
pendent on the polymer swelling, drug diffusion and matrix erosion (15).
FTIR
Fig. 2 gives the spectra of the pure drug, poloxamer, SD, xanthan gum, PEO and opti-
mized tablets. FTIR spectrum of carvedilol phosphate showed characteristic bands at 
3416.05 (overlapping of –OH and –NH stretch), 3005.2 (aromatic C-H stretch) 1504.53 (aro-
matic C=C stretch) and 1253.77 cm–1 (aromatic C-N stretch). Poloxamer exhibited absorp-
tion peaks at 3423.76 (H-bonded O-H stretch), 2889.46 (C-H aliphatic stretch) and 1112.96 
cm–1 (C-O stretch). The SD spectrum showed disappearance of the peak at 3416.05 cm–1 and 
the presence of all other carvedilol phosphate peaks with decreased intensity compared to 
the drug alone. Optimized C-X50 and C-P40 tablets showed same peaks as SD with slight 
variation. No additional peak was observed to indicate the absence of any chemical interac-
tion between the drug and poloxamers. Optimized formulations exhibited the characteris-
tic peaks of carvedilol phosphate with no additional peaks observed in the spectra, indicat-
ing retention of chemical identity of carvedilol phosphate, as shown in Fig. 2. However, the 
intensity of peaks corresponding to the drug was reduced or peaks were broadened in the 
formulations possibly due to the encapsulation of the drug with the carrier, i.e., poloxamer 
in melt granulation and possibly due to addition of other excipients. The FTIR data indicate 
the absence of chemical interaction between carvedilol phosphate and the excipients used.
Fig. 1. Dissolution data of: a) PEO formulations, b) xanthan gum tablets (mean ± SD, n = 3).
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DSC
Thermograms of the pure drug, poloxamer, SD, xanthan gum, PEO and optimized 
tablets are presented in Fig. 3. Carvedilol phosphate showed a sharp melting endotherm at 
159.1 °C, while poloxamer 188 showed a melting endotherm at 54.7 °C. Thermograms of SD 
(1:4) showed decreased peak intensity of carvedilol phosphate (155.3 °C). The melting peak 
of poloxamer in SD was observed at a slightly lower temperature (54.5 °C) than that of pure 
poloxamer 188. Reduction in intensity and shifting of the sharp melting peak of the drug in 
SD indicate that the degree of crystallinity was considerably reduced and the drug may 
have been convert to amorphous form (8). The DSC peaks revealed that there was no chem-
ical interaction between the drug and excipients used.
Fig. 2. FTIR spectra of: a) carvedilol phosphate, b) poloxamer 188, c) SD with carvedilol phosphate: 
poloxamer 188 ratio 1:4, d) xanthan gum, e) optimized C-X50 tablet, f) PEO, g) optimized C-P40 
tablet.
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CONCLUSIONS
Solid dispersion of carvedilol phosphate-poloxamer prepared with melt granulation is 
a promising method for enhancing the solubility of carvedilol phosphate. Xanthan gum 
and PEO are suitable polymers for the development of non-effervescent floating tablets of 
carvedilol phosphate. Drug release from the prepared floating tablets exhibited sustained 
release of the drug over a prolonged period of time. Future studies such as in vivo investiga-
tions are recommended to evaluate the gastric retention of selected floating tablets. Further 
studies are also recommended to evaluate the stability of formulations.
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